Pipeline
Clinic-Ready Technology
BITT has developed several TrapMAb compounds that have achieved or are rapidly approaching IND approval, including:
| TrapMAb | Target | Indications | Status |
|---|---|---|---|
| BITR2101 | TNFR2 | Oncology | IND Approved |
| BITT311 | CD40 | Autoimmunity / Inflammation | IND Enabling |
| Undisclosed | OX40 | Autoimmunity / Inflammation | Discovery |
| Undisclosed | CD27 | Autoimmunity / Inflammation | Discovery |
| Undisclosed | DR6 | Alzheimer disease | Discovery |
TNFR2/Oncology
Tumor necrosis factor receptor 2 (TNFR2) is expressed on the most potent population of TNFR2 regulatory T cells (Tregs) in the tumor microenvironment. The TNFR2 epitope is densely expressed on the immunosuppressive Tregs that protect tumors and play a role in resistance to checkpoint inhibitors, including PD1 and CTLA4. TNFR2 is also expressed on the surface of certain cancers as an NFkB-driven growth receptor oncogene.
CD40/Autoimmunity
CD40 is a TNFR superfamily member that mediates T-dependent B cell responses and efficient T cell priming. CD40 has been identified as playing a role in autoimmune diseases in which activated T and B cells cause pathology, including autoimmune thyroiditis, type 1 diabetes, inflammatory bowel disease, psoriasis, multiple sclerosis, rheumatoid arthritis, and systemic lupus erythematosus.
